Inactief instrument

Andere talen CymaBay Therapeutics, Inc.

Aandelen

CBAY

US23257D1037

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gilead Sciences Announces Completion of Acquisition of CymaBay	25/03
Gilead Sciences Completes $4.3 Billion Cymabay Acquisition	22/03
CymaBay Therapeutics : Acquisition/Asset Disposal - Form 8-K	22/03
CymaBay Therapeutics, Inc. Announces Board Changes	22/03
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from NASDAQ Composite Index	22/03
Gilead Sciences, Inc. completed the acquisition of CymaBay Therapeutics, Inc..	22/03
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from S&P Pharmaceuticals Select Industry Index	22/03
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from S&P TMI Index	22/03
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from S&P Global BMI Index	22/03
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from NASDAQ Biotechnology Index	15/03
Gilead Sciences Says Antitrust Waiting Period for CymaBay Therapeutics Deal Expires	11/03
CymaBay Says European Medicines Agency to Review Marketing Authorization Application for Seladelpar	04/03
CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis	04/03
CymaBay Therapeutics, Inc. Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis	04/03
CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update	28/02
CymaBay Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
CymaBay Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	21/02
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	20/02
CYMABAY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CymaBay Therapeutics, Inc. - CBAY	16/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen CymaBay Therapeutics, Inc.

Aandelen

CBAY

US23257D1037

Andere talen

Filters